Literature DB >> 11717641

Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help.

O A Rust1, R O Atlas, J Reed, J van Gaalen, J Balducci.   

Abstract

OBJECTIVE: The purpose of this study was to identify the risk factors that are associated with increased neonatal morbidity in patients who were treated for sonographic evidence of internal os dilation and distal cervical shortening during the second trimester. STUDY
DESIGN: From May 1998 to June 2000 patients between 16 and 24 weeks of gestation with the following sonographic criteria were randomly assigned to McDonald cerclage or no cerclage: internal os dilation and either membrane prolapse into the endocervical canal at least 25% of the total cervical length but not beyond the external os or a shortened distal cervix <2.5 cm. Before randomization, all patients were treated identically with an amniocentesis, multiple urogenital cultures, and therapy with indomethacin and clindamycin for 48 to 72 hours. Except for the cerclage, all patients were treated identically after randomization. Multiple variables of perinatal outcome were analyzed. A regression model with gestational age at delivery as the dependent variable was constructed and repeated with neonatal morbidity as the dependent variable. This model was applied to 3 populations: the cerclage group, the no cerclage group, and both groups combined.
RESULTS: Of the 135 patients, 20 patients declined randomization, and 2 patients were diagnosed with acute chorioamnionitis. Of the 113 patients remaining, 55 patients were randomly assigned to the cerclage group, and 58 patients were randomly assigned to the no cerclage group. There were 8 rescue cerclage procedures (4 in each group). Regression analysis showed that readmission for preterm labor, chorioamnionitis, and abruption were consistently associated with early gestational age at delivery and increased morbidity. Cerclage did not affect perinatal outcome.
CONCLUSION: The sonographic findings of second trimester internal os dilation, membrane prolapse, and distal cervical shortening likely represent a common pathway of several pathophysiologic processes. Use of cerclage does not alter any perinatal outcome variables. Increased neonatal morbidity in these patients appears to be associated with subclinical infection, preterm labor, and abruption.

Entities:  

Mesh:

Year:  2001        PMID: 11717641     DOI: 10.1067/mob.2001.118163

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  35 in total

1.  Patients with an asymptomatic short cervix (<or=15 mm) have a high rate of subclinical intraamniotic inflammation: implications for patient counseling.

Authors:  Edi Vaisbuch; Sonia S Hassan; Shali Mazaki-Tovi; Chia-Ling Nhan-Chang; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Zhong Dong; Lami Yeo; Pooja Mittal; Bo Hyun Yoon; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

Review 2.  Cervical stitch (cerclage) for preventing pregnancy loss in women.

Authors:  A J Drakeley; D Roberts; Z Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2003

3.  Clinical significance of early (< 20 weeks) vs. late (20-24 weeks) detection of sonographic short cervix in asymptomatic women in the mid-trimester.

Authors:  E Vaisbuch; R Romero; O Erez; J P Kusanovic; S Mazaki-Tovi; F Gotsch; V Romero; C Ward; T Chaiworapongsa; P Mittal; Y Sorokin; S S Hassan
Journal:  Ultrasound Obstet Gynecol       Date:  2010-10       Impact factor: 7.299

Review 4.  The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified?

Authors:  Roberto Romero; Jimmy Espinoza; Offer Erez; Sonia Hassan
Journal:  Am J Obstet Gynecol       Date:  2006-01       Impact factor: 8.661

Review 5.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

6.  Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) - Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes.

Authors:  Richard Berger; Harald Abele; Franz Bahlmann; Ivonne Bedei; Klaus Doubek; Ursula Felderhoff-Müser; Herbert Fluhr; Yves Garnier; Susanne Grylka-Baeschlin; Hanns Helmer; Egbert Herting; Markus Hoopmann; Irene Hösli; Udo Hoyme; Alexandra Jendreizeck; Harald Krentel; Ruben Kuon; Wolf Lütje; Silke Mader; Holger Maul; Werner Mendling; Barbara Mitschdörfer; Tatjana Nicin; Monika Nothacker; Dirk Olbertz; Werner Rath; Claudia Roll; Dietmar Schlembach; Ekkehard Schleußner; Florian Schütz; Vanadin Seifert-Klauss; Susanne Steppat; Daniel Surbek
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-08-12       Impact factor: 2.915

7.  17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.

Authors:  Vincenzo Berghella; Dana Figueroa; Jeff M Szychowski; John Owen; Gary D V Hankins; Jay D Iams; Jeanne S Sheffield; Annette Perez-Delboy; Deborah A Wing; Edwin R Guzman
Journal:  Am J Obstet Gynecol       Date:  2010-04       Impact factor: 8.661

8.  Management of pregnancies with cervical shortening: a very short cervix is a very big problem.

Authors:  Hee Joong Lee; Tae Chul Park; Errol R Norwitz
Journal:  Rev Obstet Gynecol       Date:  2009

Review 9.  Tocolytics used as adjunctive therapy at the time of cerclage placement: a systematic review.

Authors:  J Smith; E A DeFranco
Journal:  J Perinatol       Date:  2015-04-23       Impact factor: 2.521

10.  Timing of mid-trimester cervical length shortening in high-risk women.

Authors:  J M Szychowski; J Owen; G Hankins; J Iams; J Sheffield; A Perez-Delboy; V Berghella; D A Wing; E R Guzman
Journal:  Ultrasound Obstet Gynecol       Date:  2009-01       Impact factor: 7.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.